XIST and cancer: According to the GEO drug discovery, methotrexate was identified as a potential inhibitor targeting XIST. Methotrexate, formerly known as amethopterin, was initially developed for cancer treatment owing to its structural resemblance to folic acid and its ability to inhibit folate-dependent enzymes.